Assoc Prof Dr.Tiruveedula Gopi Krishna – Cancer Science – Best Researcher Award

Posted on by Pencis

Assoc Prof Dr.Tiruveedula Gopi Krishna - Cancer Science - Best Researcher Award

Adama Science and Technology University - Ethiopia

AUTHOR PROFILE

Google Scholar

Orcid

EARLY ACADEMIC PURSUITS

Dr. Tiruveedula Gopikrishna began his academic journey in the field of Computer Science and Engineering. His early academic pursuits laid the foundation for his future contributions in the realm of technology and information sciences.

PROFESSIONAL ENDEAVORS

Having demonstrated a keen interest in the field, Dr. Gopikrishna embarked on a professional journey that led him to the position of Assistant Professor and subsequently Associate Professor at Adama Science & Technology University in Ethiopia. His commitment to academia reflects in his multifaceted roles and responsibilities.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER SCIENCE

Dr. Gopikrishna's expertise encompasses a diverse range of subjects, including Data Science, Big Data, Artificial Intelligence, Machine Learning, Deep Learning, Distributed Systems, Data Warehousing, Data Mining, Cloud Computing, C, Python, C++, Java, Web Technologies, and SQL. His research focus extends to critical areas such as Big Data Analytics and Visualization, Software Testing Methodologies, Middleware, and the intersection of big data with cloud computing.

IMPACT AND INFLUENCE

Dr. Gopikrishna's impact is evident in the significant contributions he has made to the academic and research community. His influence extends beyond the classroom, shaping the minds of aspiring technologists and researchers under his guidance.

ACADEMIC CITES

The academic prowess of Dr. Gopikrishna is underscored by his extensive experience in teaching undergraduate and postgraduate subjects. He has been instrumental in guiding 56 undergraduate projects and supervising 4 master's degree theses, showcasing his commitment to fostering academic excellence.

LEGACY AND FUTURE CONTRIBUTIONS

As an Associate Professor, Dr. Gopikrishna has already established a legacy in academia. His dedication to shaping the next generation of tech professionals and researchers is evident. Looking forward, his future contributions are poised to further enrich the fields of Computer Science and Information Technology, leaving an indelible mark on the academic landscape.

NOTABLE PUBLICATIONS

An Improved Switch Migration Method Based Efficient Load Balancing for Multiple Controllers in Software Defined Network. 2023

DDoS Attack Detection and Classification Using Hybrid Model for Multi-controller SDN. 2023 (3)

Classification of Brain Tumor Types on Magnetic Resonance Images Using Hybrid Deep Learning Approach with Radial Basis Function Neural Network. 2022

Breast Cancer Classification from Mammogram Images Using Extreme Learning Machine-Based DenseNet121 Model. 2022 (5)

Designing and Developing Bilingual Chatbot for AssistingEthio-Telecom Customers on Customer Services. 2022

Dr. Hiu Yee Kwan – Obesity and Cancer – Women Researcher Award

Posted on by Pencis

Dr. Hiu Yee Kwan - Obesity and Cancer - Women Researcher Award

Hong Kong Baptist University - Hong Kong

AUTHOR PROFILE

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Kwan Hiu Yee's academic journey began with a strong foundation in the sciences. She earned a B.Sc. with 2nd Honors Upper Class in Biology and Biotechnology from the Faculty of Science at The University of Hong Kong (1992-1995).

PROFESSIONAL ENDEAVORS

Continuing her academic pursuits, Kwan Hiu Yee completed her Ph.D. at the Department of Physiology, Faculty of Medicine, The Chinese University of Hong Kong (2001-2006). She further honed her expertise by obtaining a Certificate in Epidemiology & Control of Infectious Diseases from the School of Public Health at The Chinese University of Hong Kong in 2005.

CONTRIBUTIONS AND RESEARCH FOCUS ON OBESITY AND CANCER

Kwan Hiu Yee's research focus has been on the intersection of physiology, public health, and Chinese medicine. Her contributions extend to the exploration of vascular ion channel targets in cardiovascular diseases, as evidenced by winning the Second Prize of China Medical Science and Technology Award in 2020.

IMPACT AND INFLUENCE

As an Associate Professor and Associate Director in the Teaching and Research Division at the Centre for Cancer & Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Kwan Hiu Yee plays a pivotal role in shaping the academic landscape.

ACADEMIC CITES

Her impactful work is reflected in numerous academic accolades, including the CUHK Young Scholars Dissertation Awards nomination in 2007 and the HKBU School Performance Award in Teaching in 2022.

LEGACY AND FUTURE CONTRIBUTIONS

Kwan Hiu Yee's legacy is marked by her active involvement in professional memberships, such as the International Society for Extracellular Vesicles and the Hong Kong Association for the Study of Obesity and Cancer. With a diverse skill set, including a Master of Arts in Translation & Linguistics, she continues to contribute to academia.

NOTABLE PUBLICATIONS

Elevated extracellular matrix protein 1 in circulating extracellular vesicles supports breast cancer progression under obesity conditions. 2024

Artesunate treats obesity in male mice and non-human primates through GDF15/GFRAL signalling axis. 2024

Brevilin A is a potent anti-metastatic CRC agent that targets the VEGF-IL6-STAT3 axis in the HSCs-CRC interplay. 2023 (3)

Control of SARS-CoV-2 infection by MT1-MMP-mediated shedding of ACE2. 2022 (6)

Omics approach to reveal the effects of obesity on the protein profiles of the exosomes derived from different adipose depots. 2022

Dr. Takashi Takeshita – Cancer Genetics – Best Researcher Award

Posted on by Pencis

Dr. Takashi Takeshita - Cancer Genetics - Best Researcher Award

Kumamoto City Hospital - Japan

Author Profile

Google Scholar

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Takashi Takeshita initiated his academic journey by obtaining a Medical Doctorate (M.D.) from the National Defense Medical College, Saitama, Japan, in 2005. He furthered his education by earning a Ph.D. from St. Marianna University School of Medicine, Kanagawa, Japan, in 2012. These early academic pursuits established the foundation for his future contributions to cancer genetics.

PROFESSIONAL ENDEAVORS

Since 2022, Takashi Takeshita has been serving as the Chief of Breast and Endocrine Surgery at Kumamoto City Hospital, Japan. His professional journey is marked by significant achievements, including the receipt of several prestigious awards: the 2017 Research Award from the Japanese Breast Cancer Society, the 2017 Research Award from the Japanese Society of Medical Oncology, the 2018 Young Investigatorā€™s Award from the Japan Surgical Society, and the 2018 Excellent Presentation Award from the Japanese Breast Cancer Society.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICSĀ 

Takashi Takeshita's 19-year research career spans various research institutes, showcasing a robust expertise in cancer genetics. His focus includes genetic analysis of clinical specimens, utilizing techniques such as digital PCR for tumor tissue and plasma DNA, immunohistochemical staining, automated assay robot operation, and more. His experience in large-scale cell culture and comprehensive knowledge of molecular biology, pharmacology, and analytical methods underscore his dedication to advancing cancer research.

IMPACT AND INFLUENCE

The awards received by Takashi Takeshita, coupled with his role as the Chief of Breast and Endocrine Surgery, affirm his impact and influence in the medical field. His leadership and contributions to cancer genetics, particularly in breast cancer research, position him as a prominent figure. His membership in esteemed academic societies, including the Japanese Breast Cancer Society, Japan Surgical Society, Japanese Cancer Association, Japanese Society of Medical Oncology, and the American Association for Cancer Research, further reflects his influence on a global scale.

ACADEMIC CITES

Takashi Takeshita's involvement in renowned academic societies and receipt of research awards suggest that his work likely receives recognition and citations within the scientific community. His expertise in genetic analysis and clinical research contributes to the advancement of cancer genetics literature.

LEGACY AND FUTURE CONTRIBUTIONS HIGHLIGHT

Takashi Takeshita's legacy is built upon a foundation of excellence in cancer genetics, marked by numerous awards and leadership roles. His dedication to advancing breast and endocrine surgery and his contributions to genetic analysis techniques set the stage for a lasting impact. Looking ahead, Takeshita is poised to continue making significant contributions to cancer genetics, shaping the future landscape of research in breast cancer and beyond. His membership in international societies signifies a commitment to global collaboration and further advancements in cancer research.

NOTABLE PUBLICATIONS

Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing. 2024

Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment. 2023

Development of a Machine Learning-Based Prognostic Model for Hormone Receptor-Positive Breast Cancer.Ā 2023 (5)

Fulvestrant plus palbociclib in advanced or metastatic hormone.Ā 2023 (2)

High dose of dexamethasone attenuates docetaxel-induced fluid retention in breast cancer treatment. 2023

Prof Dr. Qiao Li – Tumor Immunology – Best Researcher Award

Posted on by Pencis

Prof Dr. Qiao Li - Tumor Immunology - Best Researcher Award

University of Michigan - United States

AUTHOR PROFILE

Scopus

EARLY ACADEMIC PURSUITS

Qiao Li, Ph.D., embarked on her academic journey with a Bachelor's degree in Microbiology from Wuhan University, Wuhan, P.R. China, in 1982. Continuing her pursuit of knowledge, she obtained a Master's degree in Environmental Biology from the Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, P.R. China, in 1985. These early academic pursuits laid the foundation for her comprehensive training in the biological sciences.

PROFESSIONAL ENDEAVORS

In 1994, Qiao Li achieved a Ph.D. in Biological Sciences from Wayne State University, Detroit, Michigan, USA. Subsequently, she assumed the role of Research Professor of Tumor Immunology and Immunotherapy at the University of Michigan Medical School, Ann Arbor, Michigan, USA. Her professional endeavors showcase a commitment to advancing the understanding and treatment of cancer through immunological approaches.

CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR IMMUNOLOGY

Qiao Li's contributions extend beyond her role as a Research Professor. As a Section Editor or Editorial Board Member for the International Journal of Biological Sciences, she actively contributes to the dissemination of scientific knowledge. Her research focus lies in Tumor Immunology and Cancer Immunotherapy, where she explores innovative strategies to harness the immune system for effective cancer treatment.

IMPACT AND INFLUENCE

Qiao Li's impact is evident in her multifaceted role, including positions such as Section Editor and Editorial Board Member. Her influence extends to teaching, research mentorship, and overseeing graduate student committees at the University of Michigan. As a Research Professor, she contributes significantly to the advancement of tumor immunology, leaving a lasting imprint on the academic and research community.

ACADEMIC CITES

Qiao Li's involvement as a Section Editor and Editorial Board Member suggests that her work likely receives recognition within the academic community. Her contributions to the International Journal of Biological Sciences and other scholarly activities contribute to the dissemination and acknowledgment of her expertise in the field.

LEGACY AND FUTURE CONTRIBUTIONS HIGHLIGHT

Qiao Li's legacy is built upon her extensive involvement in education, research mentorship, and editorial roles. Her commitment to supervising undergraduate and graduate students, along with her contribution to medical student educational activities, underscores her dedication to fostering the next generation of scientists. Looking ahead, Qiao Li is poised to continue making significant contributions to tumor immunology and cancer immunotherapy, leaving a lasting legacy through her ongoing research, mentorship, and editorial responsibilities. Her role in training international Ph.D. students further signifies a global impact in the field of cancer research.

NOTABLE PUBLICATIONS

Cancer stem cell antigen nanodisc cocktail elicits anti-tumor immune responses in melanoma. 2022

Efficacy of an ALDH peptide-based dendritic cell vaccine targeting cancer stem cells. 2022

Emerging concepts regarding pro- and anti tumor properties of B cells in tumor immunity. 2022

CPNE8 Promotes Gastric Cancer Metastasis by Modulating Focal Adhesion Pathway and Tumor Microenvironment. 2022

Targeting cancer stem cells via integrin Ī²4. 2022

Dr. Hang Hu – Cancer Photodynamic Therapy – Best Researcher Award

Posted on by Pencis

Dr. Hang Hu - Cancer Photodynamic Therapy - Best Researcher Award

Changzhou University - China

AUTHOR PROFILE

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Hang Hu initiated his academic journey with a Bachelor's degree in Applied Chemistry from Hubei University. Subsequently, he pursued higher education, obtaining both a Master's degree and a Doctor's degree in Organic Chemistry and Biopharmaceutical Engineering at Huazhong University of Science and Technology. These early academic pursuits laid the foundation for his specialization in cancer photodynamic therapy.

PROFESSIONAL ENDEAVORS

Hang Hu ventured into professional academia, securing a teaching position at the School of Pharmacy, Changzhou University. His professional endeavors aligned with his research interests, focusing specifically on advancing cancer photodynamic therapy and leveraging his expertise to contribute to the development of anticancer drug delivery systems.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER PHOTODYNAMIC THERAPY

Hang Hu's significant contributions revolve around his involvement in a groundbreaking project during his graduate studies. This project aimed to construct anticancer drug delivery systems using hydroylethyl starch-based materials, leading to the development of nanomedicines tailored for cancer photodynamic therapy. His subsequent research at Changzhou University focused on novel strategies to potentiate photodynamic therapy (PDT), addressing challenges such as tumor hypoxia, high intracellular glutathione (GSH), and insufficient photosensitizer uptake.

IMPACT AND INFLUENCE

Hang Hu's impact is underscored by the recognition his research has garnered in esteemed journals such as Materials Today Bio, Journal of Colloid and Interface Science, Nanoscale, ACS Applied Materials & Interfaces, Chemical Engineering Journal, and Advanced Healthcare Materials. His work addresses critical limitations in cancer treatment methodologies, particularly in the realm of photodynamic therapy.

ACADEMIC CITES

Hang Hu's academic achievements are evident through his co-authorship of over 40 SCI papers and the application of over 30 invention patents. His prolific publication record, mainly in the fields of anticancer drug delivery and cancer photodynamic therapy, serves as a valuable reference within the scientific community.

LEGACY AND FUTURE CONTRIBUTIONS HIGHLIGHT

Hang Hu's legacy is characterized by a commitment to excellence and innovation in cancer therapy, particularly in the field of photodynamic therapy. His work has provided new insights into the design of effective cancer photodynamic therapy nanomedicines. Looking ahead, Hang Hu is poised to continue making significant contributions to enhance cancer treatment methodologies, leaving a lasting impact on the development of novel and effective therapeutic strategies. His dedication to addressing critical challenges in cancer therapy sets the stage for a continued legacy of innovative research.

NOTABLE PUBLICATIONS

Polyethylene glycol modified protamine-chlorin e6 conjugate nanoparticles for enhanced cancer photodynamic therapy. 2024

Synthesis of curcumin derivatives for suppression of castration-resistant prostate cancer. 2024

Targeted Delivery of Doxorubicin to Hepatoma Cells by Lactobionic Acid-Decorated Dual Redox-Responsive Polyethylene Glycol-Doxorubicin Nanoparticles. 2023

Synthesis and evaluation of curcumin functionalized calcium polyphosphate for bone regeneration. 2023

Reduction-responsive worm-like nanoparticles for synergistic cancer chemo-photodynamic therapy. 2023

 

Assist Prof Dr. Juan Yakisich – Cancer Cell Biology – Best Researcher Award

Posted on by Pencis

Assist Prof Dr. Juan Yakisich - Cancer Cell Biology - Best Researcher Award

Hampton University - United States

AUTHOR PROFILE

Google Scholar

Orcid

EARLY ACADEMIC PURSUITS

Juan Sebastian Yakisich, MD, PhD, pursued an interdisciplinary biomedical research path, obtaining his doctoral education at the esteemed Karolinska Institute in Europe, one of the largest and most prestigious medical universities. His early academic pursuits laid the foundation for his expertise in cell & molecular biology, cancer biology & molecular oncology, and pharmacology.

PROFESSIONAL ENDEAVORS

Following his doctoral education, Dr. Yakisich undertook postdoctoral training at the Department of Molecular and Cellular Medicine, Texas A&M University, College Station, TX. His professional journey also included a highly competitive and prestigious research grant from the Swedish Research Council, leading to four additional years as a project leader at the Department of Clinical Neuroscience, Karolinska Institute.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER CELL BIOLOGY

Dr. Yakisich possesses a comprehensive background in cancer cell biology and pharmacology, specializing in cellular and molecular biology, anticancer drug screening, and cancer stem cell biology. His significant contributions include the development of a groundbreaking cancer stem cell model (The stemness phenotype model) applicable to various cancer types, with substantial clinical implications. Additionally, he pioneered effective strategies for anticancer drug screening, addressing limitations in existing programs.

IMPACT AND INFLUENCE

As an oncology researcher, Dr. Yakisich has made a substantial impact, contributing to the understanding and treatment of various cancers, including brain tumors, cervical, lung, and breast cancers. His work has not only shaped research directions but has practical applications in clinical settings, improving the screening of oncology markers and enhancing drug delivery into cancer cells.

ACADEMIC CITES

Dr. Yakisich's academic achievements are reflected in his publication record, including over 60 peer-reviewed original articles and reviews in international leading journals. He has served as a grant and postdoctoral fellowship reviewer for NASA and held editorial and associate board memberships in international peer-reviewed journals such as Frontiers in Pharmacology.

LEGACY AND FUTURE CONTRIBUTIONS HIGHLIGHT

In his tenure at Hampton University, Dr. Yakisich has continued to contribute significantly, publishing over twenty-five peer-reviewed articles and three book chapters. His commitment to education is evident through mentoring and training Master's, PhD, undergraduate, and high school students in multiple countries. Dr. Yakisich emphasizes a commitment to mentor and train underrepresented minorities in basic and translational research, leaving a lasting legacy of diversity and inclusion.

FUTURE CONTRIBUTIONS

Looking ahead, Dr. Yakisich is actively engaged in the development of aptamer-based biomedical tools for identifying oncology markers, pathogen detection and elimination, and drug delivery into cancer cells. His dedication to mentoring and training underscores a commitment to advancing scientific knowledge and fostering the next generation of researchers, ensuring a continued impact on the field of biomedical research.

NOTABLE PUBLICATIONS

A short post reattachment ultra-sensitive window of time in human cancer cells as therapeutic target of prolonged low dose administration of specific compounds. 2024

Two-Step Preparation of Protein-Decorated Biohybrid Quantum Dot Nanoparticles for Cellular Uptake. 2023

Phenotypic Characterization of 2D and 3D Prostate Cancer Cell Systems Using Electrical Impedance Spectroscopy. 2023

Downregulation of DKK-1 and Upregulation of B - Catenin in Cancer Floating Spheroids is Associated with Chemoresistance to Wnt Signaling Pathway Inhibitors. 2022

Translational Gap in Lung Cancer Research. 2022